ASCO GU 2024

Combination vs. monotherapy - a great new option for…

Is "more" always better?

Cabo + IO: Interesting but not practice changing?!

Insights and news for mCRPC

What about the clinical benefit?

Salvage radiation with anti-androgen superior to…

Higher radiation is effective in high-risk PCA

Enzalutamide therapy as option for biochemical…

Cognitive function in ART treatment

First positive study of IO therapy in mCRPC

Further testing before olaparib combination

Evaluating the recombination-repair mutations in…

Combination NHT + PARP makes sense

Localized PCa - news for radiotherapy and biochemical…

Relugolix combined with androgen signaling in real word…

Therapy Intensification Still Neglected in mHSPC

Still a difficult time for androgenic inhibitors in…

Long-term dose escalation - Therapy in high-risk…

Stockholm3 validated in multiethnic cohort

Combination of cabozantinib & checkpoint inhibitor

Dose de-escalation in different ways

Quality of life under intensive therapy

Gleason 3+3 - cancer or not?

BRCAaway - PARP combination study

mCRPC de Olaparib+Abi , tek tek herbirinden ustun

SEPTA calismasi: Stockholm3 un multietnik hasta…

Une période encore difficile pour les inhibiteurs…

BRCAAway - PARP hämmare, abiraterone eller i…

PCa Tedavisinde Deeskalasyon (Tedavi Azaltimi) Orta…

Gleason 3+3 ska vi kalla de cancer eller inte?

Kognitiv påverkan av abirateron och enzalutamid?

Kombination av cabozantinib och immunterapi

Post-RP salvage radyoterapi hormonoterapi ile konbine…

New standard of care, but still open questions!

The emerging field of biomarkers in bladder cancer

ADC + ICI: new data for platinum-refractory bladder…

Adjuvant Nivolumab Shows Promise in Boosting Long-Term…

Should we start forgetting the Galsky Criteria in…

MIBC: adjuvant PD1 - all set?!

ASCO GU24 - Highlights in Bladder cancer

Highlights in bladder cancer at ASCO GU24

EV as standard in 3rd line mUC

Another success for an ICI?

Perioperative adjuvant therapy in urothelial cancer

Update on EV-302

Adjuvant therapy in urothelial carcinoma : is the…

Update M1 urothelial cancer

HER2 and bladder cancer

Biomarker update

EV + Pembro new first-line standard in localized…

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

¿Deberíamos empezar a olvidarnos de los Criterios de…

Encore un succès pour une ICI ?

Novedades sobre EV-302

Terapia adyuvante perioperatoria en el cáncer de vejiga

Adjuvant therapy in kidney cancer: Is immunotherapy the…

Subcutaneous vs. intravenous application: ready for…

Trial updates at ASCO GU24: Are the follow-up data…

Better QoL with Belzutifan

Perioperative treatment in renal cell carcinoma - did…

Highlights in kidney cancer at ASCO GU24

Subcutaneous Nivolumab Matches IV Formulation in Clear…

Practice changing adjuvant therapy?!

Long-Term Data on NIVO+IPI in aRCC

Nivolumab/Cabozantinib Outshines Sunitinib in Landmark…

Durable effects of Ipi-Nivo

Long-term follow-up of first-line trials

Long-term outcome

ASCO GU24 - Highlights in renal cell carcinoma

Tumorburden and outcome

Overall survival benefit - Pembro after surgery

Cabozantinib Plus Atezolizumab in Adrenocortical…

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24